Connor, Clark & Lunn Investment Management Ltd. Nuvation Bio Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 422,260 shares of NUVB stock, worth $958,530. This represents 0.01% of its overall portfolio holdings.
Number of Shares
422,260
Previous 396,736
6.43%
Holding current value
$958,530
Previous $912,000
23.14%
% of portfolio
0.01%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding NUVB
# of Institutions
168Shares Held
146MCall Options Held
3.2KPut Options Held
98.7K-
Decheng Capital LLC Menlo Park, CA26MShares$58.9 Million14.81% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$36.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.7MShares$35.7 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA13.1MShares$29.7 Million53.05% of portfolio
-
Octagon Capital Advisors LP New York, NY9.2MShares$20.9 Million5.46% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $493M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...